{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:22:09Z","timestamp":1757618529768,"version":"3.44.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03286-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:29:00Z","timestamp":1752139740000},"page":"4447-4463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of Atopic Dermatitis in Patients Initiating Systemic Therapies in the United States"],"prefix":"10.1007","volume":"42","author":[{"given":"Matthew","family":"Zirwas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Princic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan K.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamir","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-9306","authenticated-orcid":false,"given":"Lorenzo","family":"Sabatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"issue":"10","key":"3286_CR1","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590\u20138.","journal-title":"Am Fam Physician"},{"issue":"Suppl 2","key":"3286_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13223-018-0281-6","volume":"14","author":"S Kapur","year":"2018","unstructured":"Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"3286_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2310\/6620.2007.06034","volume":"18","author":"JM Hanifin","year":"2007","unstructured":"Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82\u201391.","journal-title":"Dermatitis"},{"issue":"2","key":"3286_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","volume":"184","author":"MR Laughter","year":"2021","unstructured":"Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, Dellavalle RP, Flohr C. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017. Br J Dermatol. 2021;184(2):304\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3286_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155\u201362.","journal-title":"J Allergy Clin Immunol"},{"key":"3286_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-319-64804-0_8","volume":"1027","author":"AS Adamson","year":"2017","unstructured":"Adamson AS. The economics burden of atopic dermatitis. Adv Exp Med Biol. 2017;1027:79\u201392.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"3286_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26\u201330.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3286_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84\u201392.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"3286_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","volume":"8","author":"AB Fishbein","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91\u2013101.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3286_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bjd.18925","volume":"183","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Williams KA, Grossberg AL, Kwatra MM, Kwatra SG. Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. Br J Dermatol. 2020;183(1):182\u20134.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3286_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"1","key":"3286_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1\u201321.","journal-title":"Stat Sci"},{"issue":"1","key":"3286_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/epirev\/mxab003","volume":"43","author":"N Greifer","year":"2022","unstructured":"Greifer N, Stuart EA. Matching methods for confounder adjustment: an addition to the epidemiologist\u2019s toolbox. Epidemiol Rev. 2022;43(1):118\u201329.","journal-title":"Epidemiol Rev"},{"issue":"7","key":"3286_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jech.2004.029496","volume":"60","author":"MA Hern\u00e1n","year":"2006","unstructured":"Hern\u00e1n MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60(7):578\u201386.","journal-title":"J Epidemiol Community Health"},{"issue":"6","key":"3286_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/aje\/kwz268","volume":"189","author":"JE Ripollone","year":"2020","unstructured":"Ripollone JE, Huybrechts KF, Rothman KJ, Ferguson RE, Franklin JM. Evaluating the utility of coarsened exact matching for pharmacoepidemiology using real and simulated claims data. Am J Epidemiol. 2020;189(6):613\u201322.","journal-title":"Am J Epidemiol"},{"issue":"25","key":"3286_CR16","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"2","key":"3286_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.anai.2017.10.037","volume":"120","author":"DA Hill","year":"2018","unstructured":"Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"3286_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155\u201362.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3286_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"3286_CR20","doi-asserted-by":"publisher","first-page":"e2423563","DOI":"10.1001\/jamanetworkopen.2024.23563","volume":"7","author":"YH Jang","year":"2024","unstructured":"Jang YH, Choi E-Y, Lee H, Woo J, Park S, Noh Y, Jeon J-Y, Yoo E-Y, Shin J-Y, Lee YW. Long-term use of oral corticosteroids and safety outcomes for patients with atopic dermatitis. JAMA Netw Open. 2024;7(7):e2423563\u2013e2423563.","journal-title":"JAMA Netw Open"},{"key":"3286_CR21","doi-asserted-by":"crossref","unstructured":"Opa\u0142ka B, \u017bo\u0142nierczuk M, Grabowska M. Immunosuppressive agents-effects on the cardiovascular system and selected metabolic aspects: a review. J Clin Med, 2023;12(21).","DOI":"10.3390\/jcm12216935"},{"issue":"12","key":"3286_CR22","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","volume":"12","author":"AN Fasseeh","year":"2022","unstructured":"Fasseeh AN, Elezbawy B, Korra N, Tannira M, Dalle H, Aderian S, Abaza S, Kal\u00f3 Z. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653\u201368.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"3286_CR23","first-page":"69","volume":"28","author":"X Wang","year":"2022","unstructured":"Wang X, Boytsov NN, Gorritz M, Malatestinic WN, Goldblum OM, Wade RL. US Health care utilization and costs in adult patients with atopic dermatitis by disease severity. J Manag Care Spec Pharm. 2022;28(1):69\u201377.","journal-title":"J Manag Care Spec Pharm"},{"key":"3286_CR24","doi-asserted-by":"crossref","unstructured":"Suh DC, Sung J, Gause D, Raut M, Huang J, Choi IS. Economic burden of atopic manifestations in patients with atopic dermatitis\u2013analysis of administrative claims. J Manag Care Pharm. 2007;13(9):778\u201389.","DOI":"10.18553\/jmcp.2007.13.9.778"},{"issue":"5","key":"3286_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s13555-023-00920-4","volume":"13","author":"SM Ferrucci","year":"2023","unstructured":"Ferrucci SM, Tavecchio S, Marzano AV, Buffon S. Emerging systemic treatments for atopic dermatitis. Dermatol Ther (Heidelb). 2023;13(5):1071\u201381.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03286-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:41:35Z","timestamp":1757209295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03286-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03286-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthew Zirwas is a consultant an investigator or a speaker for AbbVie, Acrotech, Advanced Derm Solutions, Aldeyra, All Free Clear\/Sun, Amgen, Anaptys, Apogee, Arcutis, Basuch and Lomb, Beiersdorf, Biocon, Bristol Myers Squibb, Cara, Dermavant, Edessa Biotech, Evelo, Galderma, Google, Incyte, Janssen, L\u2019Oreal, Leo, Level-Ex, Lilly, LUUM, Meta, Nimbus, Novan, Novartis, Pfizer, Q32 Bio, Regeneron, Sanofi, Supernus, Takeda, Trevi, Trifecta, UCB, Verrica. Nicole Princic and Megan Richards are employees of Merative which was funded by Galderma to conduct this study. Aamir Qureshi and Lorenzo Sabatelli are employees and own shares of Galderma. Peter Lio is on the speaker's bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay\/L\u2019Oreal, Pfizer, Pierre-Fabre Dermatologie, Regeneron\/Sanofi Genzyme, Verrica; reports consulting\/advisory boards for Alphyn Biologics (stock options), AbbVie, Almirall, Amyris, Arcutis, ASLAN, Bristol-Myers Squibb, Burt\u2019s Bees, Castle Biosciences, Codex Labs (stock options), Concerto Biosci (stock options), Dermavant, Eli Lilly, Galderma, Janssen, LEO Pharma, Lipidor, L\u2019Oreal, Merck, Micreos, MyOR Diagnostics, Regeneron\/Sanofi Genzyme, Skinfix, Suneco Technologies (stock options), Theraplex, UCB, Yobee Care (stock options). In addition, Dr. Lio has a patent pending for a Theraplex product with royalties paid and is a Board member and Scientific Advisory Committee Member emeritus of the National Eczema Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All database records are statistically de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, this study was exempted from Institutional Review Board approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}